MBX 6180 / MBX Biosci - LARVOL DELTA

Nomination of MBX 6180 as GLP-1/GIP/GCG triple agonist prodrug development candidate (The Manila Times) - "The Company today announced nomination of MBX 6180 as its lead GLP-1/GIP/glucagon (GCG) triple agonist prodrug candidate, further expanding its obesity pipeline to potentially address the full spectrum of patient needs. MBX 6180 combines GLP-1, GIP and GCG receptor agonist activity in a single construct. The differentiated design of MBX 6180 is intended to provide a pharmacokinetic profile supporting once-monthly dosing. The Company expects to present preclinical data from MBX 6180 at a scientific meeting in the fourth quarter of 2026. IND-enabling studies are now underway."

Pipeline update • Preclinical • Obesity